Eagle Asset Management Inc Cyma Bay Therapeutics, Inc. Transaction History

Eagle Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$4.23 - $6.55 $16,357 - $25,328	-3,867 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$5.73 - $9.03 $22,157 - $34,919	3,867 New	3,867 $21,000
Q4 2019 Feb 07, 2020	SELL	$1.33 - $5.93 $3.11 Million - $13.8 Million	-2,334,861 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$5.12 - $7.21 $2.25 Million - $3.16 Million	-438,790 Reduced 15.82%	2,334,861 $12 Million
Q2 2019 Aug 05, 2019	SELL	$6.05 - $13.66 $1.44 Million - $3.25 Million	-237,972 Reduced 7.9%	2,773,651 $19.9 Million

Q1 2019 May 01, 2019	BUY	$8.16 - $13.42 $1.29 Million - $2.13 Million	158,650 Added 5.56%	3,011,623 $40 Million
Q4 2018 Feb 11, 2019	BUY	$6.54 - $11.74 $53,673 - $96,350	8,207 Added 0.29%	2,852,973 $22.5 Million
Q3 2018 Nov 08, 2018	BUY	$10.88 - $14.52 $8.5 Million - $11.4 Million	781,700 Added 37.89%	2,844,766 $31.5 Million
Q2 2018 Aug 07, 2018	BUY	$10.66 - $14.38 $22 Million - $29.7 Million	2,063,066 New	2,063,066 $27.7 Million

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.